Prevalence and Outcomes of COVID 19 Patients with Happy Hypoxia | IDR – Dove Medical Press

Introduction

Coronavirus Disease 2019 (COVID-19) is a contagious disease that first appeared in Wuhan, China in late December 2019. It is caused by the virus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a highly transmissible virus.1,2 The disease has spread all over the world, considered a pandemic by the WHO since March 11, 2020.3 As of August 30, 2022, the world has 599,071,265 confirmed cases and 6,467,023 deaths.4 The clinical forms can be asymptomatic, mild, moderate, severe, and critical.5 Although pulmonary manifestations are common, the disease can affect several organs of the body.6

The main symptoms of Coronavirus disease 2019 (COVID-19) are fever, cough, and dyspnea.7 Some patients present with dyspnea in the setting of severe respiratory distress with a drop in oxygen saturation or oxygen partial pressure.8 Despite the absence of dyspnea, some patients with COVID-19 may have a markedly reduced oxygen saturation as measured by pulse oximetry. This phenomenon is referred to as silent hypoxia or happy hypoxia.9 Each time there has been a major wave of COVID-19, medical facilities have been overwhelmed, resulting in a rapid increase in the number of patients receiving home treatment. As a result, several deaths were recorded among patients treated at home, which became a social problem. Happy hypoxia has been one of the causes of death in COVID-19 patients receiving home care, as the absence of respiratory difficulty despite the presence of hypoxemia delays the seeking of medical care.10

The prevalence of COVID-19 patients with happy hypoxia was variable depending on the definitions of happy hypoxia used, the age of the patients, comorbidities, and the regions where the studies were conducted.11 The prevalence ranged from 31.9 to 65% in Europe11,12 and from 4.8 to 21. 5% in Asia.10,13,14 The prevalence was 4.8 in one American country15 and 6% in one African country.16 A systematic review would be beneficial in aggregating these disparities in prevalence. In addition, some studies have shown that patients with both COVID-19 and happy hypoxia are known to have poor outcomes.11,16 Therefore, hypoxemia in patients with COVID-19 without dyspnea should be identified and monitored carefully.

It is important to identify risk factors for hypoxemia in patients with COVID-19 without dyspnea. No worldwide prevalence survey of this phenomenon has been conducted. This review aimed to summarize information on the prevalence, risk factors, and outcomes of patients with happy hypoxia in order to improve their management.

Relevant studies will be identified through a search of MEDLINE, Europe PMC, and the Cochrane Library. The following will be the primary search terms in MEDLINE: ((COVID-19 [Title/Abstract]) OR (SARS-CoV-2 [Title/Abstract]) OR (coronavirus [Title/Abstract]), which will be cross-referenced to the terms (happy hypoxia [Title/Abstract]) OR (silent hypoxia [Title/Abstract]) The search will be in the English language. The search period runs from December 1st, 2019 to April 1st, 2022. The site preprints.org will search for preprints using the terms COVID-19 or Coronavirus. Official reports from medical societies, governmental institutes, and registries will also be manually searched and included if they match the inclusion criteria. The protocol was recorded on PROSPERO CRD42022293727.

Design

All observational studies report the prevalence, risk factors, and outcomes of happy hypoxia in COVID-19.

Study setting

Worldwide.

Population

All hospitalized patients infected with COVID-19

Publication status

All published and unpublished articles.

Language

Only studies reported using the English language.

Publication date

Published from the December 1st, 2019 to April 30, 2022

Patients who had received oxygen prior to hospitalization.

Two independent investigators assessed the results of the initial search for the title and abstract relevancy. The whole text was checked to see if it met the eligibility criteria. Duplicate articles, reviews, editorials, case reports, family studies, and publications that exclusively report on pediatric cases will be eliminated. Clinical studies that did not explicitly state death as a possible outcome will be ruled out. Furthermore, if a single author published two or more studies on the same patient sample, only the highest-quality publication was considered. Authors, year of publication, nation, study design, study location (number of study sites), sample size, age, sex, outcome, the definition of happy hypoxia, and proportion of happy hypoxia will be all included on data extraction forms. Two investigators (researchers with a masters degree in medicine or the humanities and clinical research experience) independently obtained this information. A third investigator double-checked the list of papers and data to make sure there were no duplicates and to rule out any inconsistencies.

The NewcastleOttawa Scale (NOS) was used to evaluate the quality of the included retrospective cohort studies based on three primary components: study patient selection which is worth up to 4 points, and adjustment for potential confounding variables which are worth up to 2 points, and outcome measurement which is worth up to 3 points.17 Each study can receive a maximum of nine points based on this scale. Articles with a NOS score of 5 were deemed high-quality publications in this study. The quality assessment was conducted by two reviewers. Disagreements were handled by discussion among reviewers, with the assistance of a third party if necessary to reach a consensus.

We will extract the authors, year of publication, nation, study design, study location (number of study sites), sample size, age, sex, the definition of happy hypoxia and proportion of happy hypoxia, gender (male/female), patient comorbidities, and outcome. We performed a meta-analysis of proportions (and 95% CI) for the prevalence of COVID-19 patients with happy hypoxia. The statistical heterogeneity among the included studies will be measured by the Cochrans Q with the p-value, and the extent of heterogeneity attributable to heterogeneity will be measured by the I2 statistic. The descriptive analyses will be performed using Stata version 14.

Through electronic database searches and registries, a total of 70 records were collected, with 25 records being eliminated before screening owing to duplication. Then, out of the 45 articles found, 20 were eliminated due to irrelevant titles, abstracts, or texts. A total of 25 papers were chosen for the full-text review, with 18 being deleted due to the lack of a result of interest, repeat data, or insufficient sample size. Finally, the research looked at seven studies (Figure 1).

Figure 1 Prisma Flow chart of study selection.

The methodological quality was high and the risk of bias was low, with a median Newcastle-Ottawa scale score of 77% (extreme values 7788%). The detailed quality assessment of all included studies can be found in Appendix A.

In total, 7 studies1016 were included in the review. The time period for the studies was 20202021. All studies were published between 2020 and 2021. The studies had sample sizes ranging from 141 to 21,544. One study was conducted in Africa (DRC);16 two studies in Europe, France, and Italy,11,12 three studies in Asia (Japan, India, and Saudi Arabia);10,13,14 and one study in the Americas (Mexico).15 In addition, only one study was prospective,15 and the rest were retrospective cohorts. Six studies took place in a single hospital, while one study in Japan involved Japanese national registries.10 Two studies defined happy hypoxia with an oxygen saturation threshold < 90%, two studies with a threshold < 94%, one study with a threshold< 95% also combining Pa O2 and PCO2, one study used the saturation threshold < 80%, one used the PaO2/Fi02 ratio < 300 mm Hg (Table 1)

Table 1 Study Characteristics of COVID-19 Patients with Happy Hypoxia

All studies reported the prevalence of happy hypoxia (Table 2). The prevalence varied from 4.8 to 65% for all definitions. In a 2020 study, Brouqui et al used an oxygen saturation of 93% as a definition. et al reported in the 2nd largest cohort a very high prevalence of 65% of happy hypoxia situations (Table 2). The pooled prevalence of the 7 studies is 6% (Figure 2).

Table 2 Prevalence of Happy Hypoxia in COVID-19

Figure 2 Pooled Prevalence of happy hypoxia in COVID-19 patients.

Brouqui et al11 discovered risk factors for poor clinical outcomes during follow-up (death/transfer to ICU) in patients without dyspnea. Hypoxemia/hypocapnia syndrome (yellow dots) was clustered with death/ICU, elevated NEWS score, age, male, and elevated D-dimers. Hypoxia/hypocapnia was linked to aging, maleness, and chronic heart disease but not to type 2 diabetes. Death/ICU was strongly associated with hypoxemia/hypocapnia syndrome (OR 95% CI: 4.37; 2.129.03) (p= 0.0001), as were elevated D-dimers > 2.5 mg/l (OR 95% CI: 6.26; 1.9919.75) (p = 0.002). Sirohiya et al14 found that multivariable logistic regression models were fitted to calculate the odds of death with silent hypoxia as the explanatory variable and other clinical, laboratory, and treatment parameters as covariates. We found that though these models showed a higher odds of death among patients with silent hypoxia, none of them were statistically significant. Akiyama et al10 found that hypoxemia without dyspnea was associated with age > 65 years (95% CI: 2.9204.350, p < 0.001), male sex (95% CI: 1.0701.600, p = 0.0087), BMI > 25 kg/m2 (95% CI: 1.1601.500, p = 0.036), chronic obstructive pulmonary disease (COPD) (95% CI: 1.3003.100, p = 0.002), other chronic lung disease (95% CI: 1.0603.400, p = 0.031), and diabetes mellitus (CI: 1.2401.850, p < 0.001). The hypoxemia without dyspnea group had a greater median respiratory rate (RR) than the control group (31/min vs 18/min, p=0.001).

All studies revealed mortality rates among patients with happy hypoxia. Mortality ranged from 1 to 45.4%. The study with a mortality of 45.4% used SpO2 < 94% as a criterion (Table 3). The pooled mortality rate of the studies was 2% (Figure 3).

Table 3 Mortality of Patients with Happy Hypoxia

Figure 3 Pooled mortality rate of patients with happy hypoxia.

Five studies reported other outcomes.1013,15 Four studies reported admission to ICU.11-13,15 According to studies by Alhusain et al, patients with dyspnea were admitted to ICU more frequently than those with happy hypoxia (107 (64%) versus 9 (36%), p = 0.007); and Brouqui et al (31(5.1%) versus 16 (1.4%), p=0.001). For the other 3 studies, the difference was not significant.5,8 Alhusain et al13 reported that the length of stay in the ICU did not differ between dyspnea and happy hypoxia on admission. Patients with dyspnea had a longer length of stay, though the difference was not statistically significant (2 (22%) vs 37 (35%), p=0.783). One study reported the need for ECMO.10 ECMO was used more frequently in patients with happy hypoxia in Japan, 57 (5.1%) vs 221 (1%) (Akiyama et al). (Table 4).

Table 4 Other Outcomes of Patients with Happy Hypoxia

To our knowledge, this was the first large-scale systematic review on the prevalence and outcome of COVID-19 patients with happy hypoxia. This is an understudied topic, with only eight studies specifically reporting the prevalence, risk factors, and outcome of COVID-19 patients with happy hypoxia. Of these, by far the largest cohort was from Japan.

The prevalence of happy hypoxia depends on the definition of happy hypoxia used. Considering all the definitions used, the prevalence of happy hypoxia ranged from 4.8% to 65%. The pooled prevalence was 6%. The highest prevalence of 65% was reported in the study in France, where oxygen saturation of less than 95% was considered in the definition of happy hypoxia. In the same study, in the subset of patients with at least one blood gas analysis (n = 161) who did not have dyspnea on admission, 28.1% had hypoxemia/hypocapnia syndrome, defining asymptomatic hypoxia.11 This value is still higher than the pooled prevalence in this systematic review. There were 2 studies reporting a low prevalence of 4.8%.10,15 One of these studies from Japan had happy definitions of hypoxia with a value of less than 94% while the other study from Mexico had a threshold of less than 80%, which could also explain the low prevalence. Compared with the results of a recent systematic review and meta-analysis on hypoxia in children infected with COVID-19 in low and moderate resource settings, considering the definition of hypoxia with saturation below 90%, the pooled prevalence was 31%.18 When compared to patients with hypoxia and dyspnea who were intubated, the prevalence of patients with hypoxia who were intubated was 28% (95% CI 20%-38%, I 2 = 63%). with a mortality rate of 14% (95% CI 7.424.4%) among these patients.19

Early intubation in COVID-19 has not shown many benefits. The literature does not find significant differences in mortality between the early intubation group and never intubated patients.20

Akiyama et al found that hypoxemia without dyspnea was associated with age > 65 years, male sex, BMI > 25 kg/m2, smoking history, chronic obstructive pulmonary disease (COPD), another chronic lung disease, and diabetes mellitus.10 These same factors are associated with severe forms and mortality related to COVID-19. Patients with COVID-19 with any of these characteristics may have hypoxemia and remain non-dyspneic. Thus, close monitoring of these patients is necessary. Specifically, they should be provided with transcutaneous oximeters so that they can monitor their own SpO2 regularly. Brouqui et al also found that patients with happy hypoxemia were elderly and chronically ill. Diabetic patients were 1.8 times more likely to have poor respiratory perception than non-diabetic controls and therefore had the lowest scores.11 It is well recognized that chronic conditions like diabetes and aging can desensitize the respiratory center, which can lead to happy hypoxia.21

The hypoxemia without dyspnea group had a greater median respiratory rate (RR) than the control group (31/min vs 18/min, p= 0.001). This finding implies that tachypnoea is an important indicator of hypoxemia, even in the absence of dyspnea. Furthermore, RR is an indicator of severe dysfunction in many-body systems, not just the respiratory system.22 It is therefore important that COVID-19 patients and their families know how to predict hypoxemia, even without transcutaneous oximetry, to ensure prompt medical management before the disease becomes severe.10 Brouqui et al found that factors associated with poor clinical outcomes during follow-up (death/transfer to ICU) among patients without dyspnea Hypoxemia/hypocapnia syndrome were clustered with death/ICU, elevated NEWS score, age, male, and elevated D-dimers.11 Hypoxemia and elevated D-dimers strongly suggest that the resulting lung damage is due in part to arterial microemboli and might explain the severity of clinical presentation and the subsequent death. These findings reinforce the recommendation to apply thrombosis prophylaxis in these patients.23

Anticoagulants are crucial for treating microvascular and microvascular thrombosis and inflammation in COVID-19 patients.2426 They also prevent the development of DIC,27 and they help to reduce mortality.28,29 The 28-day mortality was consistently lower in those who got anticoagulation compared to those who did not use.30,31

All studies showed mortality rates among patients with happy hypoxia. Mortality ranged from 1 to 45.4%. The study with a mortality of 45.4% used SpO2 < 94% as a criterion. The pooled mortality of the studies was 2%. A high mortality of 45.4% was found in the Sirohoya study in India.14 Similarly, a study in the UK reported room air oxygen saturation as a significant predictor of patient outcome and mortality.32 This is also confirmed by a Peruvian study reporting that oxygen saturation below 90% on admission was a significant predictor of in-hospital mortality in patients with COVID-19.33 Another study concluded that low oxygen levels on admission were strongly associated with more critical illness and mortality.34 The mortality rate for COVID-19 patients with severe disease can reach 61%.35,36 The primary factor is progressive hypoxia, which damages multiple associated organs, including the lungs.7 The use of standard mechanical ventilation in COVID-19 patients can result in mortality of up to 86%, in contrast to usual ARDS.3739 Before the advanced stage of COVID-19, when edema and shunt develop, High flow nasal oxygen (HFNO) should be taken into account as a superior option for early oxygen therapy. Supraglottic jet oxygenation and ventilation (SJOV) is an option, but more research is required to substantiate it.40

Four studies reported admission to the ICU.1113,15 According to studies by Alhusain et al (107 (64%) versus 9 (36%), p = 0.007) and Brouqui et al (31(5.1%) versus 16 (1.4%), p=0.001),11,13 patients with dyspnea were admitted to ICU more frequently than those with happy hypoxia. For the other 3 studies, the difference was not significant. According to Alhusain et al, the length of stay in the intensive care unit did not differ between dyspnea and happy hypoxia on admission. Patients with dyspnea had a longer length of stay, though the difference was not statistically significant (2 (22%) versus 37 (35%), p= 0.783). Two studies reported the need for ECMO.4,7 In Japan, ECMO was used more often in patients with happy hypoxia. 57(5.1) vs 221(1).10 The use of ECMO in severe COVID-19 patients seems to be the same as it is in ARDS patients that are not COVID-19.

The length of ECMO seems to be longer than in non-COVID-19 ARDS, and older age is a determinant in death.41

This lack of breathlessness deserves medical attention and should not be taken as a good sign of well-being. We suggest that for these patients with mild clinical presentation, it is particularly important to routinely achieve oxygen saturation by full pulse oximetry with blood gas analysis, if necessary, to allow early diagnosis of asymptomatic hypoxia and more appropriate management to reduce the poor outcome.11

Our systematic review had several limitations. First, we only included studies written in English. Secondly, another limitation in assessing prevalence is that the definition of happy hypoxia was inconsistent as there is not yet a standardized and validated definition. Some studies used different values of saturation, others used either PaO2 or the PaO2/FiO2 ratio. Finally, because the articles included are limited to a few nations, the global figure may not be accurate.

The pooled prevalence and mortality of patients with happy hypoxia were not very high. Happy hypoxia was associated with advanced age and comorbidities. Some patients were admitted to the intensive care unit, although fewer than dyspneic patients. Its early detection and management should improve the prognosis.

COVID-19, Coronavirus Disease 1; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; NEWS, National Early Warning Score; BMI, body mass index; NOS, NewcastleOttawa Scale; CI, confidence interval; OR, odds ratio.

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, and interpretation; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted, and agree to be accountable for all aspects of the work.

The authors report no competing interests in this work.

1. Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020;323(14):1335. doi:10.1001/jama.2020.4344

2. Gable L, Courtney B, Gatter R, et al. Global public health legal responses to H1N1. J Law Med Ethics. 2011;39(Suppl1):4650. doi:10.1111/j.1748-720X.2011.00565.x

3. Ucinotta D, Vanelli M. WHO declares COVID19 a pandemic. Acta Bio Med Atenei Parmensis. 2020;91(1):157160.

4. World Health Organization. Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who.int/. Accessed August 30, 2022.

5. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):17081720. PMID: 32109013; PMCID: PMC7092819. doi:10.1056/NEJMoa2002032

6. Johnson KD, Harris C, Cain JK, Hummer C, Goyal H, Perisetti A. Pulmonary and extra-pulmonary clinical manifestations of COVID-19. Front Med. 2020;7:526. PMID: 32903492; PMCID: PMC7438449. doi:10.3389/fmed.2020.00526

7. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):23722374. doi:10.1056/NEJMc2010419

8. Gallo Marin B, Aghagoli G, Lavine K, et al. Predictors of COVID-19 severity: a literature review. Rev Med Virol. 2021;31(1):110. doi:10.1002/rmv.2146

9. Levitan R. The infection Thats silently killing coronavirus patients; 2010. Available from: https://www.nytimes.com/2020/04/20/opinion/sunday/coronavirus-testing-pneumonia.html/. Accessed April 12, 2022.

10. Akiyama Y, Morioka S, Asai Y, et al. Risk factors associated with asymptomatic hypoxemia among COVID-19 patients: a retrospective study using the nationwide Japanese registry, COVIREGI-JP. J Infect Public Health. 2022;15(3):312314. doi:10.1016/j.jiph.2022.01.014

11. Brouqui P, Amrane S, Million M, et al. Asymptomatic hypoxia in COVID-19 is associated with poor outcome. Int J Infect Dis. 2021;102:233238. doi:10.1016/j.ijid.2020.10.067

12. Busana M, Gasperetti A, Giosa L, et al. Prevalence and outcome of silent hypoxemia in COVID-19. Minerva Anestesiol. 2021;87(3):325333. doi:10.23736/S0375-9393.21.15245-9

13. Alhusain F, Alromaih A, Alhajress G, et al. Predictors and clinical outcomes of silent hypoxia in COVID-19 patients, a single-center retrospective cohort study. J Infect Public Health. 2021;14(11):15951599. doi:10.1016/j.jiph.2021.09.007

14. Sirohiya P, Elavarasi A, Sagiraju HKR, et al. Silent Hypoxia in Coronavirus disease-2019: is it more dangerous? -A retrospective cohort study. medRxiv preprint. 2021. doi:10.1101/2021.08.26.21262668

15. Garca-Grimshaw M, Flores-Silva FD, Chiquete E, et al. Characteristics and predictors for silent hypoxemia in a cohort of hospitalized COVID-19 patients. Auton Neurosci. 2021;235:102855. doi:10.1016/j.autneu.2021.102855

16. Bepouka B, Situakibanza H, Odio O, et al. Happy Hypoxia in COVID-19 patients at Kinshasa University Hospital (the Democratic Republic of the Congo): frequency and vital outcome. J Biosci Med. 2021;9:1220. doi:10.4236/jbm.2021.92002

17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603605. doi:10.1007/s10654-010-9491-z

18. Rahman AE, Hossain AT, Nair H, et al. Prevalence of hypoxemia in children with pneumonia in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Glob Health. 2022;10(3):e348e359. doi:10.1016/S2214-109X(21)00586-6

19. Cardona S, Downing J, Alfalasi R, et al. Intubation rate of patients with hypoxia due to COVID-19 treated with awake proning: a meta-analysis. Am J Emerg Med. 2021;43:8896. doi:10.1016/j.ajem.2021.01.058

20. Mohammadi M, Khafaee Pour Khamseh A, Varpaei HA. Invasive Airway Intubation in COVID-19 patients; statistics, causes, and recommendations: a review article. Anesth Pain Med. 2021;11(3):e115868. PMID: 34540642; PMCID: PMC8438719. doi:10.5812/aapm.115868

21. ODonnell CR, Friedman LS, Russomanno JH, Rose RM. Diminished perception of inspiratory-resistive loads in insulin-dependent diabetics. N Engl J Med. 1988;319(November(21)):13691373. doi:10.1056/NEJM198811243192102

22. Cretikos MA, Bellomo R, Hillman K, Chen J, Finfer S, Flabouris A. Respiratory rate: the neglected vital sign. Med J Aust. 2008;188(11):657659. doi:10.5694/j.1326-5377.2008.tb01825.x

23. Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148150. doi:10.1016/j.thromres.2020.04.041

24. Iba T, Gando S, Thachil J. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. J Thromb Haemost. 2014;12:10101019. doi:10.1111/jth.12596

25. Mousavi S, Moradi M, Khorshidahmad T, Motamedi M. Anti-inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci. 2015;2015:507151. doi:10.1155/2015/507151

26. Hoppensteadt D, Fareed J, Klein AL, Jasper SE, Apperson-Hansen C, Lieber EA. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation. Am J Cardiol. 2008;102:842846. doi:10.1016/j.amjcard.2008.05.025

27. Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18:17471751. doi:10.1111/jth.14854

28. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:10941099. doi:10.1111/jth.14817

29. Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7:e017046. doi:10.1136/bmjopen-2017-017046

30. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18:14211424. doi:10.1111/jth.14830

31. Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2021;47:100761. PMID: 33067035; PMCID: PMC7543932. doi:10.1016/j.blre.2020.100761

32. Gupta RK, Marks M, Samuels THA, et al. Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study. Eur Respir J. 2020;56:2003498. doi:10.1183/13993003.03498-2020

33. Meja F, Medina C, Cornejo E, et al. Oxygen saturation as a predictor of mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima, Peru. PLoS One. 2020;15:e0244171. doi:10.1371/journal.pone.0244171

34. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369. doi:10.1136/bmj.m1966

35. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult in-patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:10541062. doi:10.1016/S0140-6736(20)30566-3

36. Wang D, Hu B, Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:10611069. doi:10.1001/jama.2020.1585

37. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020;46:10991102. doi:10.1007/s00134-020-06033-2

38. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475481. doi:10.1016/S2213-2600(20)30079-5

39. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. Covid-19 does not lead to a typical acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020;201:12991300. doi:10.1164/rccm.202003-0817LE

40. Jiang B, Wei H. Oxygen therapy strategies and techniques to treat hypoxia in COVID-19 patients. Eur Rev Med Pharmacol Sci. 2020;24(19):1023910246. PMID: 33090435; PMCID: PMC9377789. doi:10.26355/eurrev_202010_23248

41. Ramanathan K, Shekar K, Ling RR, et al. Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Crit Care. 2021;25(1):211. PMID: 34127027; PMCID: PMC8201440. doi:10.1186/s13054-021-03634-1

Continued here:

Prevalence and Outcomes of COVID 19 Patients with Happy Hypoxia | IDR - Dove Medical Press